8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Georgia Spencer
9.3
- - Market Access Strategy
- - 6 weeks January - February 2024
- - Pharmaceutical Company
Reviewed:
Strategic market access analysis, insightful recommendations.
The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.
Vicky Bergstrom I
8.9
- - Regulatory Submission
- - 6 weeks February 2023
- - Biotech Startup
Reviewed:
Professional and knowledgeable, seamless regulatory submission process.
Our regulatory submission was handled with great care and expertise. The process was seamless, and their knowledge of the regulatory landscape was impressive. The team's support was invaluable, and I would not hesitate to use their services again.
May Denesik
9.5
- - Gene Therapy Development
- - 12 weeks January - March 2023
- - Research Institution
Reviewed:
Innovative approach to gene therapy development, collaborative team.
The gene therapy project was managed exceptionally well, with innovative solutions provided at every stage. The team was highly collaborative and receptive to feedback, making it a truly joint effort. The results exceeded expectations.
Dr. Douglas Marquardt PhD
6.3
- - Stability Studies
- - 16 months July 2023 - November 2024
- - Pharmaceutical Company
Reviewed:
Stability studies lacked detail, required additional validation.
The stability studies conducted were lacking in detail, and we had to perform additional validation to ensure the results were reliable. This added extra time and cost to the project. The team was responsive to feedback, but the initial work was subpar.
Debbie Turner
6.5
- - Regulatory Submission
- - 8 weeks May - July 2024
- - Pharmaceutical Company
Reviewed:
Regulatory submission was incomplete, required additional work.
The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.
